Image-Guided Versus Conventional Brachytherapy for Locally Advanced Cervical Cancer: Experience of Single Institution with the Same Practitioner and Time Period
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
Abstract
Purpose This study aimed to compare treatment outcomes and toxicity profile between imaged-guided brachytherapy (IGBT) versus conventional brachytherapy (CBT) performed by the same practitioner during the same time period.Materials and Methods Medical records of 104 eligible patients who underwent brachytherapy for locally advanced cervical cancer were retrospectively reviewed. Fifty patients (48.1%) underwent IGBT, and 54 (51.9%) patients underwent CBT. All patients underwent concurrent chemoradiation with cisplatin. High-dose-rate intracavitary brachytherapy with dose prescription of 25-30 Gy in 4-6 fractions was performed for all patients. Late lower gastrointestinal (GI) and urinary toxicities occurred more than 3 months after the end of brachytherapy were included for comparative and dosimetric analyses.Results The median follow-up period was 18.33 months (range, 3.25 to 38.43 months). There were no differences in oncologic outcomes between the two groups. The IGBT group had lower rate of actuarial grade ≥ 3 toxicity than the CBT group (2-year, 4.5% vs. 25.7%; p=0.030). Cumulative equieffective D2cc of sigmoid colon was significantly correlated with grade ≥ 2 lower GI toxicity (p=0.033), while equieffective D2cc of rectum (p=0.055) and bladder (p=0.069) showed marginal significance with corresponding grade ≥ 2 toxicities in the IGBT group. Half of grade ≥ 3 lower GI toxicities impacted GI tract above the rectum. Optimal thresholds of cumulative D2cc of sigmoid colon and rectum were 69.7 Gy and 70.8 Gy, respectively, for grade ≥ 2 lower GI toxicity.Conclusion IGBT showed superior toxicity profile to CBT. Evaluating the dose to the GI tract above rectum by IGBT might prevent some toxicities.
참고문헌 (32)
- Han K, "Trends in the utilization of brachytherapy in cervical cancer in the United States", Int J Radiat Oncol Biol Phys, 87, pp.111~119 (2013)
- Lee TH, "Stereotactic ablative body radiotherapy boost for cervical cancer when brachytherapy boost is not feasible", Radiat Oncol, 16, pp.148~ (2021)
- Viswanathan AN, "Seeing is saving : the benefit of 3D imaging in gynecologic brachytherapy", Gynecol Oncol, 138, pp.207~215 (2015)
- Potter R, "MRI-guided adaptive brachytherapy in locally advanced cervical cancer(EMBRACE-I) : a multicentre prospective cohort study", Lancet Oncol, 22, pp.538~547 (2021)
- Ohno T, "A questionnaire-based survey on 3D image-guided brachytherapy for cervical cancer in Japan : advances and obstacles", J Radiat Res, 56, pp.897~903 (2015)
- 김해영, "Current status of brachytherapy in Korea: a national survey of radiation oncologists", Journal of Gynecologic Oncology, 27(4), pp.1~11 (2016), 대한부인종양학회
- 하인봉, "Who Really Benefits from 3D-Based Planning of Brachytherapy for Cervical Cancer?", Journal of Korean Medical Science, 33(18), pp.1~11 (2018), 대한의학회
- Rijkmans EC, "Improved survival of patients with cervical cancer treated with image-guided brachytherapy compared with conventional brachytherapy", Gynecol Oncol, 135, pp.231~238 (2014)
- Thomas KM, "Reduced toxicity with equivalent outcomes using three-dimensional volumetric(3DV)imagebased versus nonvolumetric point-based(NV)brachytherapy in a cervical cancer population", Brachytherapy, 16, pp.943~948 (2017)
- Derks K, "Impact of brachytherapy technique(2D versus 3D)on outcome following radiotherapy of cervical cancer", J Contemp Brachytherapy, 10, pp.17~25 (2018)
- Lim K, "Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer", Int J Radiat Oncol Biol Phys, 79, pp.348~355 (2011)
- Mayadev J, "CALLA : Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer : a phase III, randomized, double-blind, multicenter study", Int J Gynecol Cancer, 30, pp.1065~1070 (2020)
- Dose and volume specification for reporting intracavitary therapy in gynaecology, , International Commission on Radiation Units and Measurements, ~, pp.ICRU Report 38 (1985)
- Haie-Meder C, "Recommendations from Gynaecological(GYN)GEC-ESTRO Working Group(I) : concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV", Radiother Oncol, 74, pp.235~245 (2005)
- "Common Terminology Criteria for Adverse Events (CTCAE)v5.0" (2017)[URL]
- Kim YJ, "Impact of intracavitary brachytherapy technique(2D versus 3D)on outcomes of cervical cancer : a systematic review and meta-analysis", Strahlenther Onkol, 196, pp.973~982 (2020)
- Suzumura EA, "Effects of 3D image-guided brachytherapy compared to 2D conventional brachytherapy on clinical outcomes in patients with cervical cancer : a systematic review and meta-analyses", Brachytherapy, 20, pp.710~737 (2021)
- Lindegaard JC, "MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective", Acta Oncol, 52, pp.1510~1519 (2013)
- Lin AJ, "Intensity modulated radiation therapy and image-guided adapted brachytherapy for cervix cancer", Int J Radiat Oncol Biol Phys, 103, pp.1088~1097 (2019)
- Sturdza A, "Image guided brachytherapy in locally advanced cervical cancer : Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study", Radiother Oncol, 120, pp.428~433 (2016)
- Viswanathan AN, "American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part II : high-dose-rate brachytherapy", Brachytherapy, 11, pp.47~52 (2012)
- Mazeron R, "Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer : results from the prospective multicenter EMBRACE study", Radiother Oncol, 120, pp.412~419 (2016)
- Georg P, "Dose effect relationship for late side effects of the rectum and urinary bladder in magnetic resonance imageguided adaptive cervix cancer brachytherapy", Int J Radiat Oncol Biol Phys, 82, pp.653~657 (2012)
- Spampinato S, "Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer : an EMBRACE analysis", Radiother Oncol, 158, pp.312~320 (2021)
- Wachter-Gerstner N, "Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy : comparison of dose-volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point", Radiother Oncol, 68, pp.269~276 (2003)
- Holloway CL, "Sigmoid dose using 3D imaging in cervical-cancer brachytherapy", Radiother Oncol, 93, pp.307~310 (2009)
- Ko HC, "Novel use of ViewRay MRI guidance for highdose-rate brachytherapy in the treatment of cervical cancer", Brachytherapy, 17, pp.680~688 (2018)
- Chen X, "Weekly versus triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of cervical cancer : a metaanalysis", Int J Gynecol Cancer, 27, pp.344~349 (2017)
- Gouy S, "Nodal-staging surgery for locally advanced cervical cancer in the era of PET", Lancet Oncol, 13, pp.e212~20 (2012)
- "Update on CALLA Phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer" (2022)[URL]
- Schmid MP, "Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy : a comparison of spatial dose distribution within a matched-pair analysis", Radiother Oncol, 100, pp.468~472 (2011)
- Mignot F, "Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy", Gynecol Oncol, 157, pp.644~648 (2020)